Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization
暂无分享,去创建一个
S. Woo | Kyoung-Jin Min | Sang Hyun Kim | T. Kwon | S. Kang | Min Wook Kim | Eun-Woo Lee | Hyun-Shik Lee | S. Seo | Kyoung-jin Min | Hyun-Shik Lee
[1] J. Bae,et al. Alleviation of Ultraviolet B-Induced Photoaging by 7-MEGATM 500 in Hairless Mouse Skin , 2019, Toxicological research.
[2] Antonio García de Herreros,et al. TGFβ-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1. , 2018, Cancer research.
[3] Cheolju Lee,et al. K6 linked polyubiquitylation of FADD by CHIP prevents death inducing signaling complex formation suppressing cell death , 2018, Oncogene.
[4] S. Woo,et al. Z-FL-COCHO, a cathepsin S inhibitor, enhances oxaliplatin-induced apoptosis through upregulation of Bim expression. , 2018, Biochemical and Biophysical Research Communications - BBRC.
[5] Lei Shi,et al. USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis , 2018, Oncogene.
[6] A. Harris,et al. RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition , 2018, PloS one.
[7] J. Ježek,et al. Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression , 2018, Antioxidants.
[8] S. Woo,et al. Up-regulation of 5-lipoxygenase by inhibition of cathepsin G enhances TRAIL-induced apoptosis through down-regulation of survivin , 2017, Oncotarget.
[9] H. McBride,et al. mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1. , 2017, Molecular cell.
[10] G. Yoon,et al. Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP. , 2017, Antioxidants & redox signaling.
[11] R. Bjerkvig,et al. Cathepsin L silencing increases As2O3 toxicity in malignantly transformed pilocytic astrocytoma MPA58 cells by activating caspases 3/7 , 2017, Experimental cell research.
[12] J. Gécz,et al. USP9X deubiquitylating enzyme maintains RAPTOR protein levels, mTORC1 signalling and proliferation in neural progenitors , 2017, Scientific Reports.
[13] Mu-Kuan Chen,et al. Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways , 2017, Scientific Reports.
[14] M. Hall,et al. mTOR Signaling Confers Resistance to Targeted Cancer Drugs. , 2016, Trends in cancer.
[15] V. Grünwald,et al. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. , 2016, Cancer treatment reviews.
[16] S. Woo,et al. YM155 sensitizes TRAIL-induced apoptosis through cathepsin S-dependent down-regulation of Mcl-1 and NF-κB-mediated down-regulation of c-FLIP expression in human renal carcinoma Caki cells , 2016, Oncotarget.
[17] J. Dengjel,et al. The deubiquitinase Usp27x stabilizes the BH3‐only protein Bim and enhances apoptosis , 2016, EMBO reports.
[18] G. Mortier,et al. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors , 2016, British Journal of Cancer.
[19] Caihong Tan,et al. Knockdown of Cathepsin L promotes radiosensitivity of glioma stem cells both in vivo and in vitro. , 2016, Cancer letters.
[20] C. Van Noorden,et al. Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression. , 2015, Seminars in cancer biology.
[21] X. Mao,et al. SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway , 2015, Scientific Reports.
[22] Zhong-Qin Liang,et al. Cathepsin L suppression increases the radiosensitivity of human glioma U251 cells via G2/M cell cycle arrest and DNA damage , 2015, Acta Pharmacologica Sinica.
[23] Kakajan Komurov,et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. , 2014, Cancer research.
[24] Y. Yoo,et al. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression , 2014, Cell Death and Disease.
[25] Han-dong Wang,et al. Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways. , 2014, Toxicology letters.
[26] C. Schnell,et al. Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT , 2014, Clinical Cancer Research.
[27] A. Letai,et al. APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. , 2014, Developmental cell.
[28] David A. Scott,et al. Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.
[29] R. Bjerkvig,et al. Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids. , 2013, Experimental cell research.
[30] K. Flaherty,et al. TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma , 2013, Science Translational Medicine.
[31] R. Mason,et al. Inhibitors of cathepsins B and L induce autophagy and cell death in neuroblastoma cells , 2013, Investigational New Drugs.
[32] A. Feldman,et al. Ubiquitin Hydrolase UCH-L1 Destabilizes mTOR Complex 1 by Antagonizing DDB1-CUL4-Mediated Ubiquitination of Raptor , 2013, Molecular and Cellular Biology.
[33] J. S. Ahn,et al. Cathepsin D inhibits oxidative stress-induced cell death via activation of autophagy in cancer cells. , 2012, Cancer letters.
[34] F. Essmann,et al. Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. , 2012, Neoplasia.
[35] D. Sabatini,et al. mTOR Signaling in Growth Control and Disease , 2012, Cell.
[36] Sarat Chandarlapaty,et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.
[37] S. Cremers,et al. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis , 2011, Nature Reviews Rheumatology.
[38] P. Saftig,et al. Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits , 2011, BMC Neuroscience.
[39] Philip R. Gafken,et al. Identification of a Novel Bcl-2-interacting Mediator of Cell Death (Bim) E3 Ligase, Tripartite Motif-containing Protein 2 (TRIM2), and Its Role in Rapid Ischemic Tolerance-induced Neuroprotection* , 2011, The Journal of Biological Chemistry.
[40] R. Sobel,et al. Aberrant mitochondrial fission in neurons induced by protein kinase Cδ under oxidative stress conditions in vivo , 2011, Molecular biology of the cell.
[41] J. Tschopp,et al. A role for mitochondria in NLRP3 inflammasome activation , 2011, Nature.
[42] L. Holsinger,et al. Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. , 2010, Biochimie.
[43] T. M. Rünger,et al. Expression and regulation of cathepsin K in skin fibroblasts , 2009, Experimental dermatology.
[44] B. Bogerts,et al. Cathepsin K generates enkephalin from β-endorphin: A new mechanism with possible relevance for schizophrenia , 2009, Neurochemistry International.
[45] Gerard Manning,et al. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. , 2009, Cancer research.
[46] Michael S. Cohen,et al. betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. , 2009, Molecular cell.
[47] P. Bernardi,et al. Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria , 2008, Proceedings of the National Academy of Sciences.
[48] T. M. Rünger,et al. Cathepsin K in melanoma invasion. , 2008, The Journal of investigative dermatology.
[49] K. Brix,et al. Cysteine cathepsins: cellular roadmap to different functions. , 2008, Biochimie.
[50] V. Mootha,et al. mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex , 2007, Nature.
[51] D. Hanahan,et al. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. , 2007, Cancer research.
[52] C. Blackstone,et al. Cyclic AMP-dependent Protein Kinase Phosphorylation of Drp1 Regulates Its GTPase Activity and Mitochondrial Morphology* , 2007, Journal of Biological Chemistry.
[53] R. Roth,et al. PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding* , 2007, Journal of Biological Chemistry.
[54] J. P. McCoy,et al. The Mammalian Target of Rapamycin (mTOR) Pathway Regulates Mitochondrial Oxygen Consumption and Oxidative Capacity* , 2006, Journal of Biological Chemistry.
[55] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[56] K. Hruska,et al. Akt1/Akt2 and Mammalian Target of Rapamycin/Bim Play Critical Roles in Osteoclast Differentiation and Survival, Respectively, Whereas Akt Is Dispensable for Cell Survival in Isolated Osteoclast Precursors* , 2005, Journal of Biological Chemistry.
[57] E. Vuorio,et al. Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis , 2004, Annals of the rheumatic diseases.
[58] J. Avruch,et al. Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function , 2004, Genes to cells : devoted to molecular & cellular mechanisms.
[59] J. Avruch,et al. The Mammalian Target of Rapamycin (mTOR) Partner, Raptor, Binds the mTOR Substrates p70 S6 Kinase and 4E-BP1 through Their TOR Signaling (TOS) Motif* , 2003, The Journal of Biological Chemistry.